CR20120061A - Tableta - Google Patents
TabletaInfo
- Publication number
- CR20120061A CR20120061A CR20120061A CR20120061A CR20120061A CR 20120061 A CR20120061 A CR 20120061A CR 20120061 A CR20120061 A CR 20120061A CR 20120061 A CR20120061 A CR 20120061A CR 20120061 A CR20120061 A CR 20120061A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compound
- tablet
- methyl
- salt
- fluorobenzonitrile
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- IWYJYHUNXVAVAA-OAHLLOKOSA-N trelagliptin Chemical compound C=1C(F)=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 IWYJYHUNXVAVAA-OAHLLOKOSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009175695 | 2009-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20120061A true CR20120061A (es) | 2012-03-06 |
Family
ID=43529294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20120061A CR20120061A (es) | 2009-07-28 | 2012-02-08 | Tableta |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20120129878A1 (OSRAM) |
| EP (1) | EP2460523B1 (OSRAM) |
| JP (1) | JP5732394B2 (OSRAM) |
| KR (1) | KR20120039046A (OSRAM) |
| CN (1) | CN102548556A (OSRAM) |
| AU (1) | AU2010279171A1 (OSRAM) |
| BR (1) | BR112012001959A2 (OSRAM) |
| CA (1) | CA2769177A1 (OSRAM) |
| CL (1) | CL2012000182A1 (OSRAM) |
| CO (1) | CO6612226A2 (OSRAM) |
| CR (1) | CR20120061A (OSRAM) |
| EA (1) | EA201270204A1 (OSRAM) |
| EC (1) | ECSP12011699A (OSRAM) |
| IL (1) | IL217560A0 (OSRAM) |
| IN (1) | IN2012DN00954A (OSRAM) |
| MA (1) | MA33539B1 (OSRAM) |
| MX (1) | MX2012001284A (OSRAM) |
| PE (1) | PE20120919A1 (OSRAM) |
| SG (1) | SG178062A1 (OSRAM) |
| TN (1) | TN2012000031A1 (OSRAM) |
| TW (1) | TW201106991A (OSRAM) |
| WO (1) | WO2011013639A1 (OSRAM) |
| ZA (1) | ZA201200761B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5874545B2 (ja) * | 2011-06-20 | 2016-03-02 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
| US9486411B2 (en) | 2012-06-05 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Solid preparation |
| CN103768071B (zh) * | 2012-10-23 | 2016-08-17 | 中国医药工业研究总院 | 一种治疗糖尿病的口服制剂 |
| CN103877054B (zh) * | 2012-12-21 | 2016-05-25 | 北大方正集团有限公司 | 一种苯甲酸阿格列汀片剂及其制备方法 |
| CN105078974A (zh) * | 2014-05-23 | 2015-11-25 | 深圳信立泰药业股份有限公司 | 一种阿利沙坦酯固体分散体及药物组合物 |
| US20160331689A1 (en) * | 2015-05-12 | 2016-11-17 | SE Tylose USA, Inc. | Aqueous enteric coating composition |
| CN105596341B (zh) * | 2016-03-14 | 2018-08-10 | 石家庄四药有限公司 | 一种琥珀酸曲格列汀固体制剂及制备方法 |
| JP6310164B1 (ja) | 2016-05-10 | 2018-04-11 | 日本臓器製薬株式会社 | アセトアミノフェン製剤の製造方法 |
| CN114122219B (zh) * | 2020-08-28 | 2025-04-08 | 群创光电股份有限公司 | 发光单元 |
| CN116763752B (zh) * | 2023-08-24 | 2023-11-17 | 北京福元医药股份有限公司 | 一种阿卡波糖片剂及其制备方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585115A (en) * | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| EP0862562B1 (en) | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| JP2711528B2 (ja) * | 1995-12-20 | 1998-02-10 | 大洋薬品工業株式会社 | ロキソプロフェン製剤 |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF |
| PE20040609A1 (es) | 2002-11-01 | 2004-10-29 | Takeda Pharmaceutical | Compuestos heterociclicos aromaticos como promotores de un factor neurotrofico |
| WO2004041266A1 (ja) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
| EP1564213A4 (en) | 2002-11-22 | 2009-05-27 | Takeda Pharmaceutical | IMIDAZOLE DERIVATIVE, METHOD FOR THE PRODUCTION AND USE THEREOF |
| CA2527691C (en) | 2003-05-30 | 2013-01-22 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| WO2005030740A1 (ja) | 2003-09-30 | 2005-04-07 | Takeda Pharmaceutical Company Limited | チアゾリン誘導体およびその用途 |
| US7820673B2 (en) | 2003-12-17 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same, and use |
| US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| MXPA06010571A (es) | 2004-03-15 | 2007-02-16 | Takeda Pharmaceutical | Inhibidores de dipeptidil peptidasa. |
| US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
| US7517910B2 (en) | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| JP4919252B2 (ja) * | 2004-08-05 | 2012-04-18 | 株式会社明治 | 顆粒状製剤及びその製造方法 |
| EP1873144B1 (en) | 2005-04-20 | 2014-07-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| DK1897558T3 (da) * | 2005-06-09 | 2013-12-09 | Norgine Bv | Fast præparat af 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-on |
| EP1911738A4 (en) | 2005-07-29 | 2009-12-16 | Takeda Pharmaceutical | COMPOUND OF PHENOXYALKANOIC ACID |
| US8153694B2 (en) | 2005-07-29 | 2012-04-10 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| US20080009530A1 (en) | 2005-08-10 | 2008-01-10 | Hidenori Abe | Therapeutic Agent for Diabetes |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| JP2007211005A (ja) * | 2006-01-16 | 2007-08-23 | Ono Pharmaceut Co Ltd | 固形製剤用組成物および固形製剤 |
| ME00535B (me) | 2006-06-27 | 2011-10-10 | Takeda Pharmaceuticals Co | Fuzionisana ciklična jedinjenja |
| KR20170127074A (ko) | 2006-09-13 | 2017-11-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도 |
| WO2008047821A1 (en) | 2006-10-18 | 2008-04-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| US8410087B2 (en) | 2006-10-19 | 2013-04-02 | Takeda Pharmaceutical Company Limited | Indole compound |
| US20100016396A1 (en) | 2007-01-29 | 2010-01-21 | Hiroshi Imoto | Pyrazole compound |
| HRP20171518T1 (hr) * | 2007-02-01 | 2017-11-17 | Takeda Pharmaceutical Company Limited | Tabletni pripravak bez prouzrokovanja kvarova kod tabletiranja |
| KR20090106660A (ko) | 2007-02-09 | 2009-10-09 | 다케다 야쿠힌 고교 가부시키가이샤 | Ｐｐａｒ-감마의 부분 작용제로서의 축합 고리 화합물 |
| AR065698A1 (es) * | 2007-03-13 | 2009-06-24 | Takeda Pharmaceutical | Preparacion solida |
| WO2008136428A1 (ja) | 2007-04-27 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 含窒素５員複素環化合物 |
| WO2008156757A1 (en) | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Indazole compounds for activating glucokinase |
| US8400391B2 (en) | 2008-01-10 | 2013-03-19 | Honeywell International Inc. | Method and system for improving dimming performance in a field sequential color display device |
-
2010
- 2010-07-27 EA EA201270204A patent/EA201270204A1/ru unknown
- 2010-07-27 KR KR1020127005105A patent/KR20120039046A/ko not_active Withdrawn
- 2010-07-27 US US13/261,160 patent/US20120129878A1/en not_active Abandoned
- 2010-07-27 AU AU2010279171A patent/AU2010279171A1/en not_active Abandoned
- 2010-07-27 SG SG2012003984A patent/SG178062A1/en unknown
- 2010-07-27 WO PCT/JP2010/062568 patent/WO2011013639A1/ja not_active Ceased
- 2010-07-27 TW TW099124649A patent/TW201106991A/zh unknown
- 2010-07-27 CA CA2769177A patent/CA2769177A1/en not_active Abandoned
- 2010-07-27 BR BR112012001959A patent/BR112012001959A2/pt not_active Application Discontinuation
- 2010-07-27 PE PE2012000104A patent/PE20120919A1/es not_active Application Discontinuation
- 2010-07-27 CN CN2010800431623A patent/CN102548556A/zh active Pending
- 2010-07-27 IN IN954DEN2012 patent/IN2012DN00954A/en unknown
- 2010-07-27 JP JP2011524778A patent/JP5732394B2/ja active Active
- 2010-07-27 MX MX2012001284A patent/MX2012001284A/es not_active Application Discontinuation
- 2010-07-27 EP EP10804385.2A patent/EP2460523B1/en active Active
-
2012
- 2012-01-16 IL IL217560A patent/IL217560A0/en unknown
- 2012-01-20 TN TNP2012000031A patent/TN2012000031A1/en unknown
- 2012-01-23 CL CL2012000182A patent/CL2012000182A1/es unknown
- 2012-01-31 ZA ZA2012/00761A patent/ZA201200761B/en unknown
- 2012-02-08 CR CR20120061A patent/CR20120061A/es unknown
- 2012-02-24 CO CO12032481A patent/CO6612226A2/es not_active Application Discontinuation
- 2012-02-27 MA MA34653A patent/MA33539B1/fr unknown
- 2012-02-28 EC ECSP12011699 patent/ECSP12011699A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20120919A1 (es) | 2012-08-13 |
| CA2769177A1 (en) | 2011-02-03 |
| SG178062A1 (en) | 2012-03-29 |
| CL2012000182A1 (es) | 2012-10-12 |
| KR20120039046A (ko) | 2012-04-24 |
| AU2010279171A1 (en) | 2012-03-01 |
| EA201270204A1 (ru) | 2012-08-30 |
| EP2460523A4 (en) | 2014-02-26 |
| JP5732394B2 (ja) | 2015-06-10 |
| EP2460523A1 (en) | 2012-06-06 |
| IN2012DN00954A (OSRAM) | 2015-04-10 |
| EP2460523B1 (en) | 2017-01-04 |
| IL217560A0 (en) | 2012-02-29 |
| TW201106991A (en) | 2011-03-01 |
| CN102548556A (zh) | 2012-07-04 |
| JPWO2011013639A1 (ja) | 2013-01-07 |
| ECSP12011699A (es) | 2012-03-30 |
| WO2011013639A1 (ja) | 2011-02-03 |
| ZA201200761B (en) | 2013-05-29 |
| MA33539B1 (fr) | 2012-08-01 |
| TN2012000031A1 (en) | 2013-09-19 |
| MX2012001284A (es) | 2012-03-26 |
| CO6612226A2 (es) | 2013-02-01 |
| BR112012001959A2 (pt) | 2016-03-15 |
| US20120129878A1 (en) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20120061A (es) | Tableta | |
| AR112074A2 (es) | Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3 | |
| AR065698A1 (es) | Preparacion solida | |
| MX2009004767A (es) | Preparacion liquida que comprende un complejo de pimobendan y ciclodextrina. | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| JP2011088913A5 (OSRAM) | ||
| CL2012001221A1 (es) | Compuestos derivados de 4 -(1h-pirrol-1-il) pirimidin -2-ilamino y 4 -(1h-pirazol-1-il)- pirimidin-2-ilamino, inhibidores de quinasa; un compuesto isomerico; composicion farmaceutica; utiles en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, colitis ulcerante, enfermedad de crohn, bronquitis, dermatitis, entre otras. | |
| PH12012500789A1 (en) | Prolyl hydroxylase inhibitors | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| ATE542813T1 (de) | 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren | |
| MA30725B1 (fr) | Administration d'inhibiteurs de la dipeptidyl peptidase | |
| CO6382125A2 (es) | Inhibidores de proteína quinasa | |
| MY165918A (en) | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof | |
| MY151295A (en) | Pyrimidyl indoline compound | |
| IN2012DN00755A (OSRAM) | ||
| UA109421C2 (uk) | Фармацевтична композиція, яка містить ліганди сигма-рецептора | |
| EA201270216A1 (ru) | Фармацевтический состав | |
| EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| AR124688A2 (es) | Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo | |
| BR112014006248A2 (pt) | compostos de triazolopiridina como inibidores de pde10a | |
| CR20110093A (es) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos | |
| GT201400094A (es) | Formulación de liberación inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)-fenil]-benzamida | |
| PT2480232E (pt) | [4-(5-aminometil-fenil)-piperidin-1-il]-1h-indol-3-il]- metanonas dissubstituídas | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol |